For healthcare professionals only


Author's reply

BMJ 1995; 310 doi: (Published 13 May 1995) Cite this as: BMJ 1995;310:1268
  1. Hank Balfour
  1. Professor Box 437 UMHC, 15-144 PWB Harvard Street at East River Parkway, Minneapolis, MN 55455, USA

    EDITOR,—Treatment of an otherwise normal child with chickenpox is probably as controversial in the United States as it is in Britain. Clearly, costbenefit considerations are a—if not the—major issue. Acyclovir shortens the course of chickenpox by 25% to 33% overall. Of more importance is that the …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription